These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

334 related articles for article (PubMed ID: 36416738)

  • 1. Myelofibrosis.
    Passamonti F; Mora B
    Blood; 2023 Apr; 141(16):1954-1970. PubMed ID: 36416738
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Primary myelofibrosis: 2023 update on diagnosis, risk-stratification, and management.
    Tefferi A
    Am J Hematol; 2023 May; 98(5):801-821. PubMed ID: 36680511
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of myelofibrosis after ruxolitinib failure.
    Harrison CN; Schaap N; Mesa RA
    Ann Hematol; 2020 Jun; 99(6):1177-1191. PubMed ID: 32198525
    [TBL] [Abstract][Full Text] [Related]  

  • 4. How I manage anemia related to myelofibrosis and its treatment regimens.
    Verstovsek S
    Ann Hematol; 2023 Apr; 102(4):689-698. PubMed ID: 36786879
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overcoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinib.
    Bryan JC; Verstovsek S
    Cancer Chemother Pharmacol; 2016 Jun; 77(6):1125-42. PubMed ID: 27017614
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Momelotinib (JAK1/JAK2/ACVR1 inhibitor): mechanism of action, clinical trial reports, and therapeutic prospects beyond myelofibrosis.
    Tefferi A; Pardanani A; Gangat N
    Haematologica; 2023 Nov; 108(11):2919-2932. PubMed ID: 36861402
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study.
    Harrison CN; Schaap N; Vannucchi AM; Kiladjian JJ; Tiu RV; Zachee P; Jourdan E; Winton E; Silver RT; Schouten HC; Passamonti F; Zweegman S; Talpaz M; Lager J; Shun Z; Mesa RA
    Lancet Haematol; 2017 Jul; 4(7):e317-e324. PubMed ID: 28602585
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Primary myelofibrosis: 2021 update on diagnosis, risk-stratification and management.
    Tefferi A
    Am J Hematol; 2021 Jan; 96(1):145-162. PubMed ID: 33197049
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical efficacy and safety of ruxolitinib in the management of myelofibrosis: A single institution experience in Taiwan.
    Chen YY; Huang CE; Lee KD; Chen CC
    Hematology; 2016 Jan; 21(1):3-9. PubMed ID: 26214121
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis: A Randomized Clinical Trial.
    Pardanani A; Harrison C; Cortes JE; Cervantes F; Mesa RA; Milligan D; Masszi T; Mishchenko E; Jourdan E; Vannucchi AM; Drummond MW; Jurgutis M; Kuliczkowski K; Gheorghita E; Passamonti F; Neumann F; Patki A; Gao G; Tefferi A
    JAMA Oncol; 2015 Aug; 1(5):643-51. PubMed ID: 26181658
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Momelotinib expands the therapeutic armamentarium for myelofibrosis: Impact on hierarchy of treatment choices.
    Tefferi A; Pardanani A; Gangat N
    Am J Hematol; 2024 Feb; 99(2):300-308. PubMed ID: 38164985
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [JAK inhibitors for myelofibrosis: ruxolitinib and momelotinib].
    Kosugi H
    Rinsho Ketsueki; 2024; 65(8):798-809. PubMed ID: 39231711
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ruxolitinib: an oral Janus kinase 1 and Janus kinase 2 inhibitor in the management of myelofibrosis.
    Verstovsek S
    Postgrad Med; 2013 Jan; 125(1):128-35. PubMed ID: 23391678
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of JAK inhibitors in myeloproliferative neoplasms: current point of view and perspectives.
    Loscocco GG; Vannucchi AM
    Int J Hematol; 2022 May; 115(5):626-644. PubMed ID: 35352288
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Myelofibrosis: an update on drug therapy in 2016.
    Bose P; Verstovsek S
    Expert Opin Pharmacother; 2016 Dec; 17(18):2375-2389. PubMed ID: 27774820
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An evaluation of fedratinib for adult patients with newly diagnosed and previously treated myelofibrosis.
    Saleh K; Ribrag V
    Expert Rev Hematol; 2023 Apr; 16(4):227-236. PubMed ID: 36939633
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New approaches to tackle cytopenic myelofibrosis.
    Reynolds SB; Pettit K
    Hematology Am Soc Hematol Educ Program; 2022 Dec; 2022(1):235-244. PubMed ID: 36485113
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Amelioration of Myelofibrosis with Thrombocytopenia by a JAK1/2 Inhibitor, Ruxolitinib, in a Post-polycythemia Vera Myelofibrosis Patient with a JAK2 Exon 12 Mutation.
    Ikeda K; Ueda K; Sano T; Ogawa K; Ikezoe T; Hashimoto Y; Morishita S; Komatsu N; Ohto H; Takeishi Y
    Intern Med; 2017; 56(13):1705-1710. PubMed ID: 28674362
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Value and pitfalls of assessing bone marrow morphologic findings to predict response in patients with myelofibrosis who undergo hematopoietic stem cell transplantation.
    Khanlari M; Wang X; Loghavi S; Wang SA; Li S; Thakral B; Bueso-Ramos CE; Yin CC; Kanagal-Shamanna R; Khoury JD; Patel KP; Popat UR; Medeiros LJ; Konoplev S
    Ann Diagn Pathol; 2022 Feb; 56():151860. PubMed ID: 34823075
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of fedratinib for the treatment of patients with primary or secondary myelofibrosis.
    Palmer J; Mesa R
    Ther Adv Hematol; 2020; 11():2040620720925201. PubMed ID: 32477483
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.